伦康依隆妥单抗(Izalontamab Brengitecan) - 药物靶点：EGFR x HER3 x Top I_在研适应症：膀胱尿路上皮癌，复发性小细胞肺癌，三阴性乳腺癌_专利_临床

概要

基本信息

药物类型

ADC

别名

Zalontamab brengitecan、BL B01D1、BL-B01D1

+ [2]

靶点

EGFR x HER3 x Top I

作用方式

拮抗剂、抑制剂

作用机制

EGFR拮抗剂(表皮生长因子受体erbB1拮抗剂)、HER3拮抗剂(受体酪氨酸蛋白激酶erbB-3拮抗剂)、TOP1抑制剂(DNA拓扑异构酶I抑制剂)

治疗领域

肿瘤消化系统疾病口颌疾病+ [7]

在研适应症

膀胱尿路上皮癌复发性小细胞肺癌三阴性乳腺癌+ [42]

非在研适应症-

原研机构

Systimmune, Inc.初创企业

四川百利药业有限责任公司

在研机构

Systimmune, Inc.初创企业

四川百利天恒药业股份有限公司

Bristol Myers Squibb Co.

+ [2]

非在研机构-

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)临床3期

特殊审评突破性疗法 (中国)

登录后查看时间轴

结构/序列

使用我们的ADC技术数据为新药研发加速。

登录

或

查看完整样例数据

Sequence Code 43254

来源: *****

Sequence Code 10172664

来源: *****

关联

65

项与伦康依隆妥单抗相关的临床试验

NCT06926868

/ Not yet recruiting临床2/3期

A Randomized, Open-label, Inferentially Seamless Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Recurrent Inoperable,or Metastatic Triple-negative Breast Cancer (TNBC)or ER-low, HER2-negative BC Who Are Ineligible for Anti-PD1/PD-L1 Treatment

The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC) (paclitaxel, nab-paclitaxel, carboplatin plus gemcitabine, and capecitabine) for the treatment of first-line metastatic triple-negative breast cancer (TNBC) or estrogen receptor (ER)-low, human epidermal growth factor receptor 2 (HER2)-negative BC patients who are not candidates for anti-PD(L)1 therapy and endocrine therapies.

开始日期2025-07-15

申办/合作机构

Bristol Myers Squibb Co.

[+1]

CTR20250662

/ Recruiting临床3期

在既往经含铂化疗及 PD-1/PD-L1 抑制剂治疗失败的不可手术切除的局部晚期或转移性尿路上皮癌患者中对比 BL-B01D1 与医生选择的化疗方案 III 期随机对照临床研究

1）主要目的：评价BL-B01D1对比医生选择的化疗方案基于BICR评估的 PFS 获益和 OS 获益。2）次要目的：评价BL-B01D1对比医生选择的化疗方案的基于研究者评估的 PFS 获益，以及 ORR 、DCR 、DOR 的差异；评价治疗过程中不良事件（TEAE）、治疗相关不良事件（TRAE）的发生类型、频率、严重程度；评价BL-B01D1的药代动力学（PK）特征和免疫原性特征。

开始日期2025-03-25

申办/合作机构

四川百利药业有限责任公司

NCT06857175

/ Recruiting临床3期

A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma After Failure of PD-1/PD-L1 Monoclonal Antibody and Platinum-based Chemotherapy

This trial is a registered phase III, randomized, open-label and multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with recurrent or metastatic urothelial carcinoma after failure of PD-1/PD-L1 monoclonal antibody and platinum-based chemotherapy.

开始日期2025-03-25

申办/合作机构

四川百利药业有限责任公司

[+1]

100 项与伦康依隆妥单抗相关的临床结果

登录后查看更多信息

100 项与伦康依隆妥单抗相关的转化医学

登录后查看更多信息

100 项与伦康依隆妥单抗相关的专利（医药）

登录后查看更多信息

2

项与伦康依隆妥单抗相关的文献（医药）

2024-07-01·CANCER TREATMENT REVIEWS

A systematic review of antibody-drug conjugates and bispecific antibodies in head and neck squamous cell carcinoma and nasopharyngeal carcinoma: Charting the course of future therapies

Review

作者: Jiménez-Labaig, Pablo ; Braña, Irene ; Hernando-Calvo, Alberto ; Harrington, Kevin J ; Bhide, Shreerang ; Rullan, Antonio ; O'Leary, Ben ; Llop, Sandra

INTRODUCTION:

There is a need to improve the outcomes of patients with head and neck squamous cell carcinoma (HNSCC) and nasopharyngeal carcinoma (NPC), especially in recurrent unresectable and metastatic (R/M) setting. Antibody-drug conjugates (ADC) and bispecific antibodies (BsAb) may deliver promising results.

METHODS:

We conducted a systematic literature review to identify ADC and BsAb clinical trials, involving patients with HNSCC and NPC, from database creation to December 2023. We reported trial characteristics, overall response rate (ORR), overall survival (OS), and grade ≥ 3 treatment-related adverse events (trAEs).

RESULTS:

23 trials (65 % phase I) were found, involving 540 R/M patients (355 [20trials] HNSCC and 185 [5trials] NPC). There were 13 ADC (n = 343) and 10 BsAb (n = 197) trials. 96 % patients were refractory to standard of care treatments. ORR ranged from 0 to 100 %, with the highest ORR for GEN1042 plus chemoimmunotherapy. ORRs for monotherapies were 47 % for ADC, and 0-37 % for BsAb. MRG003 reached in HNSCC 43 % and NPC 47 %. BL-B01D1 54 % in NPC. Longest median OS was seen with MRG003 and KN046. Grade ≥ 3 trAEs were 28-60 % in ADC trials, and 3-33 % BsAb. Grade ≥ 3 myelosuppressive trAEs were typically seen in 8 ADC trials, while 4 BsAb showed infusion-related reactions (IRR). Four treatment-related deaths were reported (1 pneumonitis), all ADC trials.

CONCLUSION:

ADC and BsAb antibodies show promise in R/M HNSCC and NPC. Results are premature by small sample sizes and lack of control arm. ADC mainly caused myelosuppression and a pneumonitis case, and BsAb IRR. Further research is warranted in this setting.

2024-07-01·LANCET ONCOLOGY

BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study

Article

作者: Chen, Likun ; Yang, Jun ; Guo, Ye ; Chen, Gang ; Zhou, Ningning ; Zhu, Yi ; Zhou, Huaqiang ; Yang, Kunyu ; Zhou, Ting ; Fu, Zhenming ; Zhang, Li ; Xiao, Sa ; Huang, Yan ; Zhao, Shen ; Zhao, Hongyun ; Liu, Qianwen ; Li, Yongsheng ; Fang, Wenfeng ; Zhang, Yaxiong ; Han, Yaqian ; Ma, Yuxiang ; Zhu, Hai ; Zhao, Yuanyuan ; Yang, Yunpeng ; Xue, Jinhui

BACKGROUND:

Antibody-drug conjugates have promising clinical activity in the treatment of solid tumours. BL-B01D1 is a first-in-class EGFR-HER3 bispecific antibody-drug conjugate. We aimed to assess the safety and preliminary antitumour activity of BL-B01D1 in patients with locally advanced or metastatic solid tumours.

METHODS:

This first-in-human, open-label, multicentre, dose-escalation and dose-expansion phase 1 trial was conducted in seven hospitals in China, enrolling patients aged 18-75 years (dose escalation; phase 1a) or older than 18 years (dose expansion; phase 1b), with a life expectancy of at least 3 months, an Eastern Cooperative Oncology Group performance status of 0-1, and histologically or cytologically confirmed locally advanced or metastatic solid tumours that had progressed on current standard treatment. In the phase 1a i3+3 design, patients received intravenous BL-B01D1 at three different schedules: 0·27 mg/kg, 1·5 mg/kg, and 3·0 mg/kg weekly; 2·5 mg/kg, 3·0 mg/kg, and 3·5 mg/kg on days 1 and 8 of each cycle every 3 weeks; or 5·0 mg/kg and 6·0 mg/kg on day 1 of each cycle every 3 weeks. The primary objectives of phase 1a were to identify the safety, maximum tolerated dose, and dose-limiting toxicity. In phase 1b, patients were treated in two schedules: 2·5 and 3·0 mg/kg on days 1 and 8 every 3 weeks, or 4·5, 5·0, and 6·0 mg/kg on day 1 every 3 weeks. The primary objectives of phase 1b were to assess the safety and recommended phase 2 dose of BL-B01D1, and objective response rate was a key secondary endpoint. Safety was analysed in all patients with safety records who received at least one dose of BL-B01D1. Antitumour activity was assessed in the activity analysis set which included all patients who received at least one dose of BL-B01D1 every 3 weeks. This trial is registered with China Drug Trials, CTR20212923, and ClinicalTrials.gov, NCT05194982, and recruitment is ongoing.

FINDINGS:

Between Dec 8, 2021, and March 13, 2023, 195 patients (133 [65%] men and 62 [32%] women; 25 in phase 1a and 170 in phase 1b) were consecutively enrolled, including 113 with non-small-cell lung cancer, 42 with nasopharyngeal carcinomas, 13 with small-cell lung cancer, 25 with head and neck squamous cell carcinoma, one with thymic squamous cell carcinoma, and one with submandibular lymphoepithelioma-like carcinoma. In phase 1a, four dose-limiting toxicities were observed (two at 3·0 mg/kg weekly and two at 3·5 mg/kg on days 1 and 8 every 3 weeks; all were febrile neutropenia), thus the maximum tolerated dose was reached at 3·0 mg/kg on days 1 and 8 every 3 weeks and 6·0 mg/kg on day 1 every 3 weeks. Grade 3 or worse treatment-related adverse events occurred in 139 (71%) of 195 patients; the most common of which were neutropenia (91 [47%]), anaemia (76 [39%]), leukopenia (76 [39%]), and thrombocytopenia (63 [32%]). 52 (27%) patients had a dose reduction and five (3%) patients discontinued treatment due to treatment-related adverse events. One patient was reported as having interstitial lung disease. Treatment-related deaths occurred in three (2%) patients (one due to pneumonia, one due to septic shock, and one due to myelosuppression). In 174 patients evaluated for activity, median follow-up was 6·9 months (IQR 4·5-8·9) and 60 (34%; 95% CI 27-42) patients had an objective response.

INTERPRETATION:

Our results suggest that BL-B01D1 has preliminary antitumour activity in extensively and heavily treated advanced solid tumours with an acceptable safety profile. Based on the safety and antitumour activity data from both phase 1a and 1b, 2·5 mg/kg on days 1 and 8 every 3 weeks was selected as the recommended phase 2 dose in Chinese patients.

FUNDING:

Sichuan Baili Pharmaceutical.

TRANSLATION:

For the Chinese translation of the abstract see Supplementary Materials section.

351

项与伦康依隆妥单抗相关的新闻（医药）

2025-04-18

·E药经理人

三生制药抗VEGF/PD-1双特异性抗体707被纳入突破性治疗品种

近日，三生制药自主研发的抗VEGF/PD-1双特异性抗体（研发代码：707）正式被国家药品监督管理局纳入突破性治疗品种，适应症为一线治疗PD-L1表达阳性的局部晚期或转移性非小细胞肺癌。根据全球癌症统计数据，肺癌的发病率和死亡率均居于所有癌症之首，其中非小细胞肺癌约占全部肺癌的80%-85%。临床治疗中，抗PD-1/L1单药效果有限，抗PD-1/L1联合化疗的5年生存率也仅为17%-30%，且常伴随诸多化疗相关副作用。因此，寻找全新且更有效的治疗手段成为临床的迫切需求。707是三生制药基于CLF2专利平台开发的靶向VEGF/PD-1双特异性抗体，可同时抑制VEGF和PD-1双靶点。II期临床阶段性分析数据显示，707在非小细胞肺癌（NSCLC）患者的治疗上获得了优异的客观缓解率（ORR）和疾病控制率（DCR），无论单药还是与化疗联用，均展示出显著的抗肿瘤活性和良好的安全性，具有best-in-class（同类最优）的潜力。除非小细胞肺癌外，三生制药还在推进707用于治疗结直肠癌、子宫内膜癌、卵巢癌等领域的临床研究。同时，707也获得了FDA的IND批准。此外，三生制药还通过对外合作进一步拓宽707的应用前景。2月，三生制药与百利天恒达成合作，共同推进707和BL-B01D1联合用药，在中国大陆地区用于实体瘤的治疗，探索双抗+双抗ADC在肿瘤治疗上的潜在价值。根据《突破性治疗药物审评工作程序（试行）》，国家药监局药品审评中心将对纳入突破性治疗品种的药品提供政策支持，优先配置资源进行沟通交流，加强指导并促进药物研发，加快药品的上市进程。一审| 黄佳二审| 李芳晨三审| 李静芝

临床申请突破性疗法临床1期临床2期抗体药物偶联物

2025-04-16

·药研网

百利天恒第10款ADC新药BL-M09D1获批临床，拓展晚期实体瘤治疗新路径

2025年4月17日，四川百利天恒发布公告称，其自主研发的创新抗体偶联药物（ADC）—注射用BL-M09D1，已正式获得国家药品监督管理局（NMPA）签发的《药物临床试验批准通知书》，将于境内启动针对晚期实体瘤的临床研究。BL-M09D1 是与 BL-B01D1 出自同一小分子技术平台、与 BL-B01D1共享同一“连接子+毒素”平台的 ADC 药物，其适应症为晚期实体瘤。百利天恒通过推进BL-M09D1的临床发展，不仅在填补国内晚期实体瘤患者的治疗空白，还将进一步提升其在创新生物药领域的研发地位。End声明：本公众号所有发文章(包括原创及转载文章)系出于传递更多信息之目的，且注明来源和作者。本公众号欢迎分享朋友圈或大群，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载/商务/投稿 | 联系微信15618157102（sum_Gmi）商务合作稿件征集点击了解详情往期回顾1关张、破产、裁员 | 2024年生物药企的阴影2全球第一款司美格鲁肽咀嚼软糖上市！3中国首个男性HPV疫苗获批上市!

抗体药物偶联物疫苗

2025-04-16

·药事纵横

映恩生物正式登陆港交所！ADC赛道跑出50亿美元license-out神话

4月15日上午9点，映恩生物（股票代码：09606.HK）正式登陆港交所，成为近年来港股18A生物科技板块最受瞩目的IPO之一。这家专注于抗体偶联药物（ADC）研发的创新药企，以发行价区间94.60-103.20港元/股、募资总额2.1亿美元（约15.4亿港元）的成绩，不仅刷新了港股18A企业自2022年以来的融资纪录，更在暗盘交易中一度大涨80%，首日开盘股价飙升超90%至201.6港元。市场对这家成立仅6年的Biotech展现出的热情，不仅源于其ADC管线的差异化布局，更折射出中国创新药企在全球化竞争中的突围路径——以license-out（对外授权）为核心的商业模式创新，正在重塑行业生态。近几年ADC赛道爆火，映恩生物的崛起，正是踩中了这一风口。截至2024年底，该公司已建立12款自主研发的ADC管线，其中6款进入临床阶段，覆盖乳腺癌、小细胞肺癌等适应症，更凭借EGFR/HER3双特异性ADC药物DB-1418的突破性设计，在2025年初与Avenzo Therapeutics达成总金额12亿美元的授权合作，首付款5000万美元、后续里程碑付款11.5亿美元，并享有销售分成。映恩生物通过早期技术平台积累快速孵化管线，再通过对外授权实现现金流回血。数据显示，自2023年4月以来，映恩生物已完成6笔ADC药物授权交易，潜在总金额超50亿美元，合作对象包括BioNTech、百济神州、Adcendo等国际药企。仅2025年开年，就新增与Avenzo、三生制药的两项合作。这种模式的优势显而易见：一方面，企业无需承担高风险的后期临床和商业化投入，通过预付款和里程碑收入支撑研发；另一方面，国际药企则能快速补充管线，缩短开发周期。license-out模式下仍存在一些显著问题。招股书显示，公司2024年营收19.41亿元，同比增长8.6%，但营业成本激增导致毛利率从76%暴跌至40.4%，运营亏损扩大至1.89亿元，净亏损更达10.5亿元。这暴露出ADC研发的高昂成本：2024年研发开支8.37亿元，占总营收43%，而管线推进的烧钱速度远超授权收入到账节奏。另外，公司流动负债净值高达19.6亿元，且早前融资协议中包含对赌条款，若未能在2025年前上市，投资者可要求以年利率10%-30%赎回股份。尽管IPO成功暂时缓解了这一危机，但未来若管线进展不及预期，现金流压力或将加剧。映恩生物IPO的火爆，也被视为港股18A板块能否走出低谷的关键信号。自2021年资本退潮后，港股生物科技板块持续低迷：56家已上市18A企业中，19家破发，30家市值不足20亿港元。而映恩生物此次国际配售超14倍认购、暗盘大涨、首日高开，似乎重燃市场热情。基石投资者阵容堪称豪华——BioNTech、礼来亚洲基金、富国基金、易方达等15家机构合计认购6500万美元，其中BioNTech的参与尤其引人注目，暗示其可能将映恩视为ADC技术互补的战略伙伴。尽管ADC赛道火热，但同质化竞争已隐现危机。目前全球在研ADC管线中，HER2、Trop2等成熟靶点占比超60%，而映恩生物押注的EGFR/HER3双特异性ADC则属于新兴领域。这种差异化策略虽能避开红海竞争，但也面临更高科学风险。以DB-1418为例，其“1+1”双靶点设计虽在临床前显示出对耐药肿瘤的更高亲和力，但与百利天恒“2+2”设计的BL-B01D1相比，疗效和安全性尚未经过临床验证。此外，Avenzo为获得DB-1418权益，需支付总计30亿美元的里程碑款项，但其自身融资额仅3.86亿美元，若后续资金链紧张，可能影响研发投入。不过，license-out模式对企业的持续创新能力提出极高要求。映恩生物目前12条管线中，6款处于临床阶段，2款双抗ADC计划2025-2026年进入临床，这意味着未来3年需密集推进临床试验，而每项试验都可能消耗数亿元资金。若无法持续输出具有国际竞争力的新分子，现有合作的价值链可能断裂。这一点从信达生物、恒瑞医药等企业的布局可见端倪：信达的DLL3 ADC已与罗氏达成10亿美元合作，恒瑞则将同类药物授权给IDEAYA，首付款达7500万美元。映恩生物需要证明，其技术平台能持续孵化“best-in-class”产品，而非依赖单款爆品。映恩生物的上市，既是中国创新药企凭借ADC技术弯道超车的缩影，也折射出行业在资本寒冬中的生存智慧。通过license-out模式，企业得以在研发早期获取资金、分散风险，同时借助国际药企的渠道加速全球化。但这种模式的可持续性，始终建立在临床数据过硬、管线迭代迅速的基础上。对于映恩生物而言，上市只是马拉松的第一公里，未来需要在高估值压力下，用实实在在的疗效数据证明自己。信息来源：[1] 映恩生物，成功在香港上市，早盘大涨逾1.27倍. 新浪财经药事纵横投稿须知：稿费已上调，欢迎投稿

IPO抗体药物偶联物引进/卖出财报

100 项与伦康依隆妥单抗相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
膀胱尿路上皮癌	临床3期	中国	四川百利药业有限责任公司	2025-03-25
复发性小细胞肺癌	临床3期	中国	四川百利药业有限责任公司	2024-08-07
三阴性乳腺癌	临床3期	中国	四川百利药业有限责任公司	2024-06-21
EGFR突变的非小细胞肺癌	临床3期	中国	四川百利药业有限责任公司	2024-05-22
转移性非鳞状非小细胞肺癌	临床3期	中国	四川百利药业有限责任公司	2024-05-22
HR阳性乳腺癌	临床3期	中国	四川百利药业有限责任公司	2024-04-24
HR阳性/HER2阴性乳腺癌	临床3期	中国	四川百利药业有限责任公司	2024-04-24
食管鳞状细胞癌	临床3期	中国	四川百利药业有限责任公司	2024-03-19
转移性食管鳞状细胞癌	临床3期	中国	四川百利药业有限责任公司	2024-03-19
鼻咽癌	临床3期	中国	四川百利药业有限责任公司	2023-12-04

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05262491 (ESMO2024) 人工标引	临床1期	食管鳞状细胞癌	83	BL-B01D1 2.0 mg/kg	夢憲築顧憲襯憲觸廠艱(淵鹽製鑰窪餘醖淵網壓) = The incidence of ≥ G3 TRAEs at 2.5 mg/kg was 53%, and the most common ≥G3 TRAEs were anemia (25%), leukopenia (18%), thrombocytopenia (18%), neutropenia (15%), lymphocyte count decreased (15%) 蓋積鬱遞醖艱選築衊範 (獵鹽壓選醖積壓襯糧壓 ) 更多	积极	2024-09-16
NCT05262491 (ESMO2024) 人工标引	临床1期	食管鳞状细胞癌	83	BL-B01D1 2.5 mg/kg		积极	2024-09-16
NCT05262491 (BL-B01D1, ESMO2024) 人工标引	临床1期	胆道癌	39	BL-B01D1 2.5 mg/kg	夢範觸構蓋憲繭鬱窪製(艱觸鏇廠鹹構鑰繭餘齋) = 蓋鬱窪鬱顧夢鏇鏇艱鏇襯餘鹽選鹽壓構構願淵 (積獵鏇蓋積憲築蓋鑰繭 ) 更多	积极	2024-09-16
NCT05785039 (BL-B01D1, ESMO2024)	临床1/2期	转移性尿路上皮癌	32	BL-B01D1 2.2 mg/kg	蓋淵獵願淵觸衊鏇選淵(選網範範範網膚齋壓憲) = 22%/0% at 2.2mg/kg 鑰餘製蓋壓範鬱鹹構糧 (積襯餘窪觸觸顧繭願餘 ) 更多	积极	2024-09-13
CTR20212923 \| NCT05194982 (Pubmed) 人工标引	临床1期	实体瘤	195	BL-B01D1 0.27 mg/kg	窪齋顧遞淵繭艱壓餘壓(網積網蓋襯鹽築夢壓餘) = 簾範淵壓廠糧選製築餘窪襯構艱夢鹹蓋製簾窪 (鬱積積選淵構壓壓壓鬱 ) 更多	积极	2024-07-01
NCT05470348 (PRNewswire) 人工标引	临床1期	乳腺癌 ER Negative \| HER2 Negative \| PR Negative \| ... 更多	127	BL-B01D1	憲衊觸製鏇齋觸廠壓糧(鏇鏇築願鏇衊顧鹹顧廠) = 憲製艱繭鬱鬱鹹獵網衊襯網醖製獵餘鏇範範壓 (齋遞積製艱衊淵網夢簾 ) 更多	积极	2023-12-05
NCT05194982 (ESMO 12023 \| ESMO 22023) 人工标引	临床1期	非小细胞肺癌 EGFR	114	BL-B01D1	壓壓壓觸遞膚製繭憲鹽(範願鏇膚膚鬱襯淵壓觸) = 獵醖膚廠鬱廠蓋願築簾衊選顧憲糧觸繭構獵網 (蓋餘襯艱淵顧膚鏇憲膚 )	积极	2023-10-21
NCT05194982 (ESMO 12023 \| ESMO 22023) 人工标引	临床1期	非小细胞肺癌 EGFR	114	BL-B01D1 (EGFRmut)	衊膚鹹顧鹹鹹膚獵壓築(選築衊網鏇製觸艱壓觸) = 構顧衊齋鹽選憲蓋範顧繭餘淵衊鑰構膚網鑰鑰 (繭齋鏇廠繭鹹願獵範夢, 75.2 ~ 97.1) 更多	积极	2023-10-21
NCT05194982 (ASCO 12023 \| ASCO 22023) 人工标引	临床1期	转移性实体瘤	120	BL-B01D1 (EGFRmut + NSCLC)	獵構襯簾構鏇衊醖糧獵(蓋糧醖顧憲糧範獵鑰繭) = neutropenia, febrile neutropenia and thrombocytopenia at 3.0mg/kg QW and 3.5mg/kg D1D8 Q3W 網範膚遞膚襯襯壓夢窪 (膚願積壓糧壓壓蓋繭簾 ) 更多	积极	2023-05-31
NCT05194982 (ASCO 12023 \| ASCO 22023) 人工标引	临床1期	转移性实体瘤	120	BL-B01D1 (EGFRwt + NSCLC)		积极	2023-05-31